Top Stories
L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM
Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM
Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

Natco Pharma's Vizag facility gets two observations from USFDA
Natco Pharma has announced to the exchanges regarding completion of USFDA inspection at company’s Vizag Formulation facility.
In a regulatory filing, the company informed that the completion of a regulatory inspection from the United States Food and Drug Administration (USFDA) for its Formulation facility in Ramky SEZ, near Visakhapatnam (Vizag), India, which was conducted during the period January 30, 2023 to February 03, 2023.
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure.
“The Company is confident of addressing all observations within the stipulated time”, Natco Pharma said.
At around 11:15 AM, Natco Pharma was trading at Rs531.95 per share higher by 0.71% on the BSE.
Related News

BlinkX and Google Cloud Revolutionize Indian Financial Services through ClienTech
2 mins read. May 16, 2024 at 12:40 PM

PSP Projects secures lowest bid for Dharoi Dam region project
1 mins read. November 6, 2023 at 09:23 AM

Bata strikes deal with Authentic Brands Group for Nine West
1 mins read. November 6, 2023 at 08:43 AM

Shakti Pumps secures 7th patent for Waste Water Pump innovation
2 mins read. October 31, 2023 at 07:03 AM
Download app
Access BlinkX
everywhere
across device
